
    
      Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of
      OCR-002 (ornithine phenylacetate) in Hospitalized Patients with Cirrhosis and Associated
      Hyperammonemia with an Episode of Hepatic Encephalopathy (STOP-HE Study)
    
  